Merck to Hold Second-Quarter 2010 Sales and Earnings Conference Call on July 30

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck & Co., Inc. (NYSE: MRK) will hold its second-quarter 2010 sales and earnings conference call with institutional investors and analysts beginning at 8 a.m. EDT on Friday, July 30. During the call, Richard T. Clark, chairman and chief executive officer, Kenneth C. Frazier, president, and Peter N. Kellogg, executive vice president and chief financial officer, will provide an overview of Merck’s financial performance for the quarter.

Journalists are invited to listen-only by calling (706) 758-9928 or (800) 399-7917. At the conclusion of the call, journalists who wish to ask questions are invited to call Media Relations. A replay of the call will be available starting at 11 a.m. EDT on July 30 through 5 p.m. EDT on Aug. 6. To listen to the replay, dial (706) 645-9291 or (800) 642-1687 and enter ID No. 83513814.

Investors, journalists and the general public may access a live audio webcast of the call on Merck’s Web site at http://www.merck.com/investors/events-and-presentations/home.html. Software needed to listen to the webcast is available on the corporate Web site and should be downloaded prior to the beginning of the webcast. A replay of the webcast will be available from 11 a.m. EDT on July 30 through 5 p.m. EDT on Aug. 6. The second-quarter sales and earnings news release and supplemental financial disclosures also will be available in the Newsroom.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Merck. Be well. For more information, visit www.merck.com.



CONTACT:

Merck
Media:
David Caouette, 908-423-3461
Amy Rose, 908-423-6537
or
Investors:
Alex Kelly, 908-423-5185
Joe Romanelli, 908-423-5088

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.